Clinical Trial Update: MITO-6: Capecitabine in Platinum Resistant Ovarian Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study (MITO-6) tested capecitabine in platinum-resistant ovarian cancer and the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Capecitabine (capecitabine)

Snippet

Sponsor: National Cancer Institute, Naples | Conditions: Ovarian Cancer | Phase 2 | Status: COMPLETED